⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3689816 | 1.00 | EPHX1 (0.33) | — | |
| SCHEMBL2841035 | 1.00 | — | — | |
| SCHEMBL2838082 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL17605131 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL263001 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL6082960 | 0.97 | — | — | |
| SCHEMBL3696737 | 0.97 | ROCK2 (0.34) | — | |
| Hydrochloric Acid SCHEMBL17605128 | 0.94 | — | — | |
| SCHEMBL1020014 | 0.93 | — | — | |
| SCHEMBL2836152 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3468953-B1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-05-22 | — | — | EP | claimed |
| CN-109563043-B | Substituted pyridines as inhibitors of DNMT1 | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-05-31 | — | — | CN | claimed |
| US-10975056-B2 | Substituted pyridines as inhibitors of DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | claimed |
| EP-3436017-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME (US) | 2020-09-23 | — | — | EP | claimed |
| US-20190194166-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-27 | — | — | US | claimed |
| EP-3468953-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-04-17 | — | — | EP | claimed |
| CN-109563043-A | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-04-02 | — | — | CN | claimed |
| WO-2017216727-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-12-21 | — | — | WO | claimed |
| WO-2017216726-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-12-21 | — | — | WO | claimed |
| EP-4651872-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | Septerna, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | ANGELINI PHARMA S.P.A. (IT) | 2025-03-06 | — | — | US | disclosed |
| EP-3956033-B1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS INC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-12103902-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| EP-4433453-A1 | NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS | Icagen, LLC (US) | 2024-09-25 | — | — | EP | disclosed |
| EP-1140937-A2 | ANTIVIRAL NUCLEOSIDE ANALOGUES | Shire Biochem Inc. (CA) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039143-A2 | ANTIVIRAL NUCLEOSIDE ANALOGUES | SHIRE BIOCHEM INC. (CA) | 2000-07-06 | — | — | WO | disclosed |
| US-4242359-A | ALKYL AND CYCLOALKYL SECONDARY AMINES | CORNELL RESEARCH FOUNDATION, INC. (US) | 1980-12-30 | — | — | US | disclosed |
| US-4048312-A | 2,4-Diaminoquinazolines as antithrombotic agents | ELI LILLY AND COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
| US-3979200-A | POSTEMERGENT | MONSANTO COMPANY (US) | 1976-09-07 | — | — | US | disclosed |
| US-3956495-A | 2,4-Diaminoquinazolines as antithrombotic agents | ELI LILLY AND COMPANY (US) | 1976-05-11 | — | — | US | disclosed |